Dr. Sankari Nagarajan (@snagarajanlab) 's Twitter Profile
Dr. Sankari Nagarajan

@snagarajanlab

Translational Epigenetics Research, Woman in Science, Lecturer at the University of Manchester

ID: 884508164888113152

linkhttps://www.nagarajan-lab.com/ calendar_today10-07-2017 20:22:34

508 Tweet

664 Followers

407 Following

EACR (@eacrnews) 's Twitter Profile Photo

EACR-AstraZeneca Postdoctoral Fellowships are back! 🎉 Submit your outline proposal by 24 April ⏳ If you're excited to learn more, click here for all the information: eacr.org/eacr-fellowshi…

Dr. Sankari Nagarajan (@snagarajanlab) 's Twitter Profile Photo

Anyone interested in moving to the UK and to work with our fantastic lab in translational epigenetics, please ping me. This is a great opportunity. 💪🏼💪🏼💪🏼

Division of Molecular and Cellular Function UoM (@mcf_uom) 's Twitter Profile Photo

Recent work led by Ximena Soto in collaboration with Papalopulu Lab shows how cell-to-cell communication plays a key role in compensating when the dynamics of transcription factor Her6 is altered. An exciting example of team cooperation Development! journals.biologists.com/dev/article/15…

Choudhary Lab CPR (@choudharylabcpr) 's Twitter Profile Photo

Is acetylation of proteins (and histones in particular) a cause or a consequence of gene transcription? We undertook an unbiased proteome-wide analysis of acetylation changes upon transcription inhibition and our results were just published nature.com/articles/s4146…

Breast Cancer Now (@breastcancernow) 's Twitter Profile Photo

“We are devastated and angry that womens’ lives will be shortened as a result of NICE, NHS England, Daiichi Sankyo, and AstraZeneca failing to agree a solution that would make Enhertu available on the NHS in England for thousands of people with HER2-low secondary breast cancer."

“We are devastated and angry that womens’ lives will be shortened as a result of NICE, NHS England, Daiichi Sankyo, and AstraZeneca failing to agree a solution that would make Enhertu available on the NHS in England for thousands of people with HER2-low secondary breast cancer."